Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Randomized, Subject-Blinded, Active-Controlled, Dose Escalation, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix in Healthy Adult Volunteers Between the Ages of 50 and 69 Years

Next Previous
Trial Profile

A Phase 1 Randomized, Subject-Blinded, Active-Controlled, Dose Escalation, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix in Healthy Adult Volunteers Between the Ages of 50 and 69 Years

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Z 1018 (Primary) ; GSK 137173A
  • Indications Varicella zoster virus infections
  • Focus Adverse reactions
  • Sponsors Dynavax Technologies

Most Recent Events

  • 02 May 2023 According to Dynavax media release, data from this trial has been accepted for oral presentation at the National Foundation for Infectious Diseases online 2023 Annual Conference on Vaccinology Research.
  • 09 Jan 2023 According to Dynavax media release, based on these initial data the company intends to advance its shingles vaccine candidate with CpG-1018 adjuvant into a Phase 1/2 study in early 2024 expand on these results and to evaluate various dose levels of Dynavax-manufactured gE protein.
  • 09 Jan 2023 According to Dynavax media release, the company plans to submit an abstract of these results for presentation at an upcoming medical meeting in the first half of 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top